AGTC Applied Genetic Technologies Corporation gains 16% Apr 25, 2018

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops genetic therapies to treat patients with inherited diseases. Its lead products consist of four ophthalmology development programs across three targets, including X linked retinoschisis (XLRS) that is in a Phase I/II clinical trials for the treatment of an inherited retinal disease; X-linked retinitis pigmentosa (XLRP), which is enrolling patients in a Phase I/II clinical trials; and achromatopsia (ACHM) that is enrolling patients in a Phase I/II clinical trials. Applied Genetic Technologies Corporation has collaboration agreements with Biogen MA, Inc.; 4D Molecular Therapeutics; and Synpromics Limited. The company was founded in 1999 and is headquartered in Alachua, Florida.http://www.priceseries.com/trade/AGTC-Applied-Genetic-Technologies-Corporation-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2018041120180425.html